Supreme Court Delivers Major Win for Generic Drug in Skinny Label Patent Case
The U.S. Supreme Court has handed generic drug manufacturers a significant victory in a closely watched patent dispute involving the cardiovascular medication Vascepa. In a unanimous 9-0 ruling, the Court sided with Hikma Pharmaceuticals and concluded that Amarin Pharma failed to prove that Hikma actively encouraged infringement of patents covering certain uses of the drug.
The decision overturns a 2024 ruling from the U.S. Court of Appeals for the Federal Circuit and is expected to strengthen legal protections for generic pharmaceutical companies that rely on “skinny labels” when bringing lower-cost alternatives to market.
Understanding the Vascepa Patent Dispute
The case centers on Vascepa (icosapent ethyl), a prescription medication derived from fish oil. The U.S. Food and Drug Administration (FDA) first approved the drug in 2012 for the treatment of severe hypertriglyceridemia, a condition involving dangerously high triglyceride levels in the blood.
In 2019, the FDA expanded Vascepa’s approved uses to include reducing the risk of cardiovascular events in certain patients with elevated triglycerides. Amarin obtained patents covering this newer cardiovascular indication, giving the company exclusive rights to market the drug for that specific use.
Under the Hatch-Waxman Act, however, generic drugmakers can seek approval for non-patented uses of a drug while excluding patented indications from their labels. This process is known as a “skinny label” or “carve-out.”
Hikma’s Generic Drug Launch and Amarin’s Lawsuit
In 2020, Hikma Pharmaceuticals received FDA approval for a generic version of Vascepa that included only the original indication for severe hypertriglyceridemia. The patented cardiovascular use was intentionally omitted from the label.
Amarin nevertheless filed a lawsuit, arguing that Hikma indirectly encouraged physicians to prescribe its generic product for the patented cardiovascular indication. The company pointed to press releases, website content, and other public statements that referred to Hikma’s product as a generic version of Vascepa.
According to Amarin, these communications could have influenced doctors to prescribe the generic drug for uses still protected by Amarin’s patents.
A federal district court initially dismissed the lawsuit in 2022, finding insufficient evidence of patent infringement. However, the Federal Circuit revived the case in 2024, concluding that Hikma’s statements might reasonably be interpreted as encouraging infringement.
That ruling alarmed many generic manufacturers, who feared it could expose them to increased patent litigation despite following FDA labeling requirements.
The Supreme Court’s Generic Drug Decision
When the case reached the Supreme Court, the central question was whether Hikma had actively encouraged doctors to use its generic drug for the patented cardiovascular indication.
Writing for the Court, Justice Ketanji Brown Jackson stated that Amarin failed to show more than a mere possibility that Hikma’s statements induced patent infringement. The Court emphasized that the legal standard requires evidence of active encouragement, not simply the possibility that healthcare providers could interpret statements in a particular way.
The ruling also noted that it is standard industry practice for generic manufacturers to identify their products as equivalents to branded medications. The Court declined to treat those routine communications as proof of unlawful conduct.
As a result, the Supreme Court reversed the Federal Circuit’s decision and sent the case back for further proceedings consistent with its opinion.
Broader Impact on the Generic Drug Pharmaceutical Industry
The ruling is expected to reinforce the Hatch-Waxman framework and preserve the skinny-label pathway that generic manufacturers have relied upon for decades.
Supporters of Hikma argued that a decision favoring Amarin could have discouraged companies from developing generic alternatives, potentially reducing competition and increasing prescription drug costs. Generic medicines play a critical role in lowering healthcare expenses and expanding patient access to treatment.
Amarin, on the other hand, maintained that strong patent protections are necessary to encourage companies to invest in discovering new uses for existing medications. The company argued that significant research and financial resources were required to establish Vascepa’s cardiovascular benefits.
While the decision represents a setback for Amarin, it provides greater clarity for generic drugmakers navigating patent-protected indications. Moving forward, manufacturers that properly use FDA-approved skinny labels may have stronger legal protection against claims that routine communications alone amount to patent infringement.
